LIVE WEBINAR: Wednesday, November 30, 2022, 5:00 PM – 6:00 PM Eastern Time

BCMA-Directed Therapy in Multiple Myeloma — Expert Opinions and Patient Perspectives

A 2-Part CME/MOC-Accredited Virtual Series

We are pleased to announce this 2-part live webinar series focused on the role of B-cell maturation antigen (BCMA)-directed therapy in the management of multiple myeloma. Each session will feature an exceptional faculty member in a moderated review of recent clinical research and current cases presented by consulting clinical investigators, including prerecorded conversations with the patients themselves. Both sessions will be moderated by Dr Neil Love.

Consulting Faculty

Jesús G Berdeja, MD
Director of Multiple Myeloma Research
Tennessee Oncology
Nashville, Tennessee

Natalie S Callander, MD
Director, Myeloma Clinical Program
Interim Director, Bone Marrow Transplant Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin


Neil Love, MD
Research To Practice
Miami, Florida

Schedule of Events
To register for either or both of these complimentary events, choose the corresponding link below.

Session 2
S Vincent Rajkumar, MD
Mayo Clinic
Rochester, Minnesota
Wednesday | 5:00 PM – 6:00 PM Eastern Time | Webinar

Previous Event

Session 1
Elizabeth O’Donnell, MD
Dana-Farber Cancer Institute
Boston, Massachusetts

These activities are supported by educational grants from Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Regeneron Pharmaceuticals Inc.

November 30, 2022
5:00 PM – 6:00 PM Eastern Time
Live CME/MOC-accredited webinars

Topics to Be Discussed

  • MODULE 1: Optimal Integration of CAR (Chimeric Antigen Receptor) T-Cell Therapy into the Care of Patients with Multiple Myeloma (MM)
  • MODULE 2: Incorporating Belantamab Mafodotin into Current MM Treatment Algorithms
  • MODULE 3: Future Role of BCMA-Targeted Bispecific Antibodies in the Treatment of MM

Target Audience
These activities are intended for medical oncologists, nurses, radiation oncologists and other allied healthcare professionals involved in the treatment of multiple myeloma.

Learning Objectives
Upon completion of each activity, participants should be able to

  • Appraise the scientific rationale for targeting B-cell maturation antigen (BCMA) in the care of patients with multiple myeloma (MM), and assess the similarities and differences between various approved and investigational strategies directed at BCMA.
  • Appreciate available data documenting the activity of chimeric antigen receptor (CAR) T-cell therapy targeting BCMA for MM, and use this knowledge to identify patients who may be appropriate for this approach within or outside of a protocol setting.
  • Develop an understanding of the mechanism of action of and pivotal clinical trial findings with the recently FDA-approved BCMA-targeted antibody-drug conjugate belantamab mafodotin for optimal integration into MM management algorithms.
  • Evaluate the biologic rationale for and available efficacy findings with the use of BCMA-directed bispecific antibodies for MM, and identify patients for whom a clinical trial of this novel strategy should be considered and/or recommended.
  • Recognize adverse events associated with approved and investigational anti-BCMA therapies for MM, educate patients and implement strategies to manage complications.
  • Recall the designs of ongoing clinical trials evaluating novel CAR T-cell therapies, antibody-drug conjugates and bispecific antibodies as monotherapy or in combination with other systemic approaches for MM, and counsel appropriate patients about availability and participation.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of each activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Callander and Dr Rajkumar have no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr BerdejaConsulting Agreements: bluebird bio, Bristol-Myers Squibb Company, Celgene Corporation, CRISPR Therapeutics, Janssen Biotech Inc, Kite, A Gilead Company, Legend Biotech, Secura Bio, Takeda Pharmaceuticals USA Inc; Contracted Research: 2seventy bio, AbbVie Inc, Acetylon Pharmaceuticals, Amgen Inc, bluebird bio, Bristol-Myers Squibb Company, C4 Therapeutics, CARsgen Therapeutics, Cartesian Therapeutics, Celgene Corporation, Celularity, CRISPR Therapeutics, EMD Serono Inc, Fate Therapeutics, Genentech, a member of the Roche Group, GlaxoSmithKline, Ichnos Sciences, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Lilly, Novartis, Poseida Therapeutics, Sanofi, Takeda Pharmaceuticals USA Inc, Teva Oncology, Zentalis Pharmaceuticals. Dr O’DonnellAdvisory Committee: Bristol-Myers Squibb Company; Consulting Agreements: Bristol-Myers Squibb Company, Janssen Biotech Inc, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Janssen Biotech Inc, Takeda Pharmaceuticals USA Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These activities are supported by educational grants from Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Regeneron Pharmaceuticals Inc.